Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Diffuse large B-cell lymphoma (DLBCL) from primary sites and metastatic lymph nodes

ABSTRACT: Analysis of diffuse large B-cell lymphoma (DLBCL) from primary sites (named as S1, S2 and S3) and metastatic lymph nodes (named as L1, L2 and L3). Results provide insight into the targets involved in t DLBCL dissemination.

ORGANISM(S): Homo sapiens

PROVIDER: GSE81968 | GEO | 2017/06/30

SECONDARY ACCESSION(S): PRJNA323529

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Methylome analysis of epiRIL344 BC1-S1 to BC1-S6 aerial part

Project description:DNA methylation profiling in epiRIL344 BC1-S1 to BC1-S6 aerial part (epiRIL344_BC1-S1 - epiRIL344_BC1-S2 - epiRIL344_BC1-S3 - epiRIL344_BC1-S4 - epiRIL344_BC1-S5 - epiRIL344_BC1-S6) Keywords: Genome binding/occupancy profiling by genome tiling array

2012-09-03 | GSE37285 | GEO

Oxygen downshift experiment with E.coli W3110

2008-07-08 | GSE12006 | GEO

RNA sequencing of Medicago seed tissues under optimal and heat stress conditions

Project description:We analysed transcriptome changes between seed devlopement (4 stages corresponding at before (S1) and after (S2) desiccation tolerance acquisition and before (S3) and after (S4) longevity acquisition) in dissected seed tissues (embryo, E; Endosperm Eo and Seed Coat SC)

2020-11-03 | GSE160725 | GEO

Transcription profiling of E.coli W3110 oxygen downshift

Project description:Dynamical response to oxygen downshift under fermentation conditions was tested by taking sample before (S1) and after (S2, S3 and S4) the oxygen downshift. The dynamical changes relevant for ongoing research on physiology were applied. Experiment Overall Design: Four microarray chips were analyzed: Experiment Overall Design: S1 was taken 15 min before the oxygen downshift Experiment Overall Design: S2, S3 and S4 were taken 15 min, 45 min and 75 min after the oxygen downshift, respectively

2008-10-21 | E-GEOD-12006 | biostudies-arrayexpress

Hippo signaling coordinates cellular quiescence with terminal maturation in iNKT cell development and fate decisions [MoGene-2_0]

Project description:Hippo kinases Mst1 and Mst2 act as molecular rheostats for the terminal maturation and effector differentiation programs of iNKT cells. iNKT developmental stages 1, 2, and 3 (S1, S2, S3) were sorted from the thymus of WT (n = 3) and Cd4CreMst1fl/fl (n = 3) mice

2020-04-07 | GSE130043 | GEO

Identification of tRNA sequences in Lactococcus lactis

Project description:we report the identification and sequences of the tRNAome of industrially relevant microorganism Lactococcus lactis Three Next Generation sequencing runs annotated as S1, S2 and S3 were performed. Cells were harvested at exponential phase and tRNA was isolated. S1 and S2 were spiked with Phe-tRNAGAA from yeast and Lys-tRNAUUU from E. coli prior to cell lysis. S3 was spiked with Phe-tRNAGAA from yeast and Lys-tRNAUUU from E. coli before the library preparation to estimate the possible loss of tRNA in the extraction process.

2014-07-29 | E-GEOD-55392 | biostudies-arrayexpress

Methylome analysis of epiRIL344 BC1-S1 to BC1-S6 aerial part

2012-09-03 | E-GEOD-37285 | biostudies-arrayexpress

Expression profiles of 30-gene hepatocellular carcinoma molecular classification signature in surgically resected Japanese hepatocellular carcinoma patients

Project description:Background & Aims: Hepatocellular carcinoma (HCC) is the second most lethal cancer due to lack of effective therapies. Although promising, HCC molecular classification, which enriches potential responders to specific therapies, has not yet been assessed in clinical trials of anti-HCC drugs. We aimed to overcome these challenges by developing clinicopathological surrogate indices of HCC molecular classification. Methods: HCC classification defined in our previous transcriptome meta-analysis (S1, S2, and S3 subclasses) was implemented in an FDA-approved diagnostic platform (Elements assay, NanoString). Ninety-six HCC tumors (training set) were assayed to develop molecular subclass-predictive indices based on clinicopathological features, which were independently validated in 99 HCC tumors (validation set). Molecular deregulations associated with the histopathological features were determined by pathway analysis. Sample sizes for HCC clinical trials enriched with specific molecular subclasses were determined. Results: HCC subclass-predictive indices were: steatohepatitic (SH)-HCC variant and immune cell infiltrate for S1 subclass, macrotrabecular/compact pattern, lack of pseudoglandular pattern, and high serum alpha-fetoprotein (>400 ng/mL) for S2 subclass, and microtrabecular pattern, lack of SH-HCC and clear cell variants, and lower histological grade for S3 subclass. Macrotrabecular/compact pattern, a predictor of S2 subclass, was associated with activation of therapeutically targetable oncogene YAP and stemness markers EPCAM/KRT19. BMP4 was associated with pseudoglandular pattern. Subclass-predictive indices-based patient enrichment reduced clinical trial sample sizes from 121, 184, and 53 to 30, 43, and 22 for S1, S2, and S3 subclass-targeting therapies, respectively. Conclusions: HCC molecular subclasses can be enriched by clinicopathological indices tightly associated with deregulation of therapeutically targetable molecular pathways.

2015-06-17 | GSE59548 | GEO

Expression data from Diffuse Large B Cell Lymphoma (DLBCL) patients

Project description:Diffuse large B-cell lymphoma (DLBCL) is currently divided into three main molecular subtypes, defined by gene expression profiling (GEP): Germinal Center B-cell like (GCB), Activated B-Cell like (ABC), and Primary Mediastinal B-cell Lymphoma (PMBL). DLBCL subtypes were determined according to patients' gene expression profiles.

2017-01-30 | GSE87371 | GEO

IDR-Targeting Compounds Suppress HPV Genome Replication via Disruption of Phospho-BRD4 Association with DNA Damage Response Factors

Project description:Sample name abbreviation is below. Cell State: Prol for proliferation, Diff for differentiation Compound (cpd) treatment: DMSO for DMSO-only treatment, 14 or 90 for compound pNPS14 or pNPS90 treatment BRD4-L IP: L1, L2, and L3 for anti-BRD4-L IP samples 1, 2, and 3 BRD4-S IP: S1, S2, and S3 for anti-BRD4-S IP samples 1, 2, and 3 IgG IP: Ig1, Ig2, and Ig3 for IgG IP samples 1, 2, and 3 Sample ID vs. sample name is listed below. 967246 / Prol_DMSO_L1, 967247 / Prol_DMSO_L2, 967248 / Prol_DMSO_L3 967249 / Prol_14_L1, 967250 / Prol_14_L2, 967251 / Prol_14_L3 967252 / Prol_10_L1, 967253 / Prol_10_L2, 967254 / Prol_10_L3 967255 / Prol_DMSO_S1, 967256 / Prol_DMSO_S2, 967257 / Prol_DMSO_S3 967258 / Prol_14_S1, 967259 / Prol_14_S2, 967260 / Prol_14_S3 967261 / Prol_10_S1, 967262 / Prol_10_S2, 967263 / Prol_10_S3 967264 / Diff_DMSO_L1, 967265 / Diff_DMSO_L2, 967266 / Diff_DMSO_L3 967267 / Diff_14_L1, 967268 / Diff_14_L2, 967269 / Diff_14_L3 967270 / Diff_10_L1, 967271 / Diff_10_L2, 967272 / Diff_10_L3 967273 / Diff_DMSO_S1, 967274 / Diff_DMSO_S2, 967275 / Diff_DMSO_S3 967276 / Diff_14_S1, 967277 / Diff_14_S2, 967278 / Diff_14_S3 967279 / Diff_10_S1, 967280 / Diff_10_S2, 967281 / Diff_10_S3 967282 / Prol_DMSO_Ig1, 967283 / Prol_DMSO_Ig2, 967284 / Prol_DMSO_Ig3 967285 / Diff_DMSO_Ig1, 967286 / Diff_DMSO_Ig2, 967287 / Diff_DMSO_Ig3

2023-03-28 | MSV000091570 | MassIVE

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data